NASDAQ:OSUR - OraSure Technologies Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$8.21 +0.04 (+0.49 %)
(As of 05/27/2019 09:19 AM ET)
Previous Close$8.17
Today's Range$8.08 - $8.32
52-Week Range$8.08 - $17.97
Volume353,108 shs
Average Volume894,349 shs
Market Capitalization$509.43 million
P/E Ratio16.42
Dividend YieldN/A
Beta1.16
OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, OSUR and DNAG. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests. Its principal products include OraQuick ADVANCE HIV-1/2, OraQuick HIV–1/2, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV, OraQuick Ebola, OraQuick Zika, OraSure QuickFlu Rapid Flu A&B test, OraSure, Oragene DX, Oragene DNA, Oragene RNA, ORAcollect DX, ORAcollect DNA, Performagene, OMNIgene GUT, OMNIgene SPUTUM, OMNIgene VAGINAL, OMNIgene ORAL, GenoFIND, Hemagene, PrepIT, Intercept, MICRO-PLATE DOA assays, Intercept i2, homogeneous DOA assays, and professional and over-the-counter cryosurgical systems. In addition, the company manufactures and sells kits that are used to collect, stabilize, transport, and store samples of genetic material for molecular testing in the consumer genetic, clinical genetic, academic research, pharmacogenomics, personalized medicine, microbiome, and animal genetics markets. Further, it provides medical devices for the removal of benign skin lesions by cryosurgery or freezing; immunoassay tests and reagents for insurance risk assessment, substance abuse testing, and forensic toxicology applications; an oral fluid Western blot confirmatory test for confirming positive HIV-1 test; and Q.E.D. rapid point-of-care saliva alcohol test. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, and commercial and industrial entities. OraSure Technologies, Inc. was founded in 2000 and is based in Bethlehem, Pennsylvania.

Receive OSUR News and Ratings via Email

Sign-up to receive the latest news and ratings for OSUR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Supplies
SectorMedical
Current SymbolNASDAQ:OSUR
CUSIP68554V10
Phone610-882-1820

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$181.74 million
Cash Flow$0.6118 per share
Book Value$4.62 per share

Profitability

Net Income$20.40 million

Miscellaneous

Employees398
Market Cap$509.43 million
Next Earnings Date8/14/2019 (Estimated)
OptionableOptionable

OraSure Technologies (NASDAQ:OSUR) Frequently Asked Questions

What is OraSure Technologies' stock symbol?

OraSure Technologies trades on the NASDAQ under the ticker symbol "OSUR."

How were OraSure Technologies' earnings last quarter?

OraSure Technologies, Inc. (NASDAQ:OSUR) posted its earnings results on Wednesday, May, 8th. The medical instruments supplier reported ($0.05) EPS for the quarter, topping analysts' consensus estimates of ($0.06) by $0.01. The medical instruments supplier had revenue of $30.12 million for the quarter, compared to the consensus estimate of $29.66 million. OraSure Technologies had a return on equity of 7.87% and a net margin of 11.34%. The firm's revenue for the quarter was down 28.3% on a year-over-year basis. During the same period in the previous year, the business earned $0.07 earnings per share. View OraSure Technologies' Earnings History.

When is OraSure Technologies' next earnings date?

OraSure Technologies is scheduled to release their next quarterly earnings announcement on Wednesday, August 14th 2019. View Earnings Estimates for OraSure Technologies.

What guidance has OraSure Technologies issued on next quarter's earnings?

OraSure Technologies issued an update on its FY19 earnings guidance on Wednesday, May, 8th. The company provided earnings per share (EPS) guidance of $0.22-0.24 for the period, compared to the Thomson Reuters consensus estimate of $0.24. The company issued revenue guidance of $170-175 million, compared to the consensus revenue estimate of $172.79 million.OraSure Technologies also updated its Q2 guidance to approx $0.02 EPS.

What price target have analysts set for OSUR?

2 Wall Street analysts have issued 12-month price objectives for OraSure Technologies' stock. Their predictions range from $10.00 to $10.00. On average, they anticipate OraSure Technologies' stock price to reach $10.00 in the next twelve months. This suggests a possible upside of 21.8% from the stock's current price. View Analyst Price Targets for OraSure Technologies.

What is the consensus analysts' recommendation for OraSure Technologies?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OraSure Technologies in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for OraSure Technologies.

What are Wall Street analysts saying about OraSure Technologies stock?

Here are some recent quotes from research analysts about OraSure Technologies stock:
  • 1. According to Zacks Investment Research, "OraSure Technologies, Inc. develops, manufactures and markets oral fluid specimen collection devices using proprietary oral fluid technologies, diagnostic products including immunoassays and other in vitro diagnostic tests, and other medical devices. These products are sold in the United States as well as internationally to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, and commercial and industrial entities. OraSure Technologies is the leading supplier of oral-fluid collection devices and in vitro diagnostic assays to the employment, criminal justice, drug treatment, life insurance and public health markets for the detection of abused drugs and the antibodies to HIV. Based in Bethlehem, Pennsylvania, the Company develops, manufactures and markets oral specimen collection devices, in vitro diagnostic tests, and other medical devices. " (5/15/2019)
  • 2. Canaccord Genuity analysts commented, "We no longer have this conviction, and thus, we downgrade OSUR from Buy to HOLD, remove OSUR as one of our top picks, and lower our PT from $16 to $10. We acknowledge OSUR could potentially look attractive to value investors at present levels (~2.5x our ’19 revs), or possibly even to a larger company looking to do a tuck-in. Q1/19 recap. Y/Y) narrowly topped our/Street’s ~$29.7M while EPS of ($0.05) were roughly in line with our/Street’s ($0.06)/guide of ($0.06)- ($0.07)." (5/9/2019)

Has OraSure Technologies been receiving favorable news coverage?

Press coverage about OSUR stock has been trending very positive on Monday, InfoTrie reports. The research firm identifies negative and positive news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. OraSure Technologies earned a news impact score of 3.1 on InfoTrie's scale. They also gave media headlines about the medical instruments supplier a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the immediate future.

Who are some of OraSure Technologies' key competitors?

What other stocks do shareholders of OraSure Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other OraSure Technologies investors own include Silvercorp Metals (SVM), Merit Medical Systems (MMSI), Citigroup (C), Liberty Global (LBTYA), XOMA (xoma), Silvercorp Metals (SVM), Energy Transfer LP Unit (ET), Overstock.com (OSTK), Ford Motor (F) and CBL & Associates Properties (CBL).

Who are OraSure Technologies' key executives?

OraSure Technologies' management team includes the folowing people:
  • Dr. Stephen S. Tang, Pres, CEO & Director (Age 58)
  • Mr. Jack E. Jerrett, Sr. VP, Gen. Counsel & Sec. (Age 60)
  • Mr. Anthony Zezzo II, Exec. VP & Bus. Unit Leader of Infectious Disease (Age 65)
  • Mr. Brian L. Smith, Vice Chairman & EVP of Innovation - DNA Genotek, Inc. (Age 60)
  • Mr. Roberto E. Cuca, CFO & Principal Accounting Officer (Age 51)

Who are OraSure Technologies' major shareholders?

OraSure Technologies' stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (14.69%), Renaissance Technologies LLC (7.02%), Dimensional Fund Advisors LP (5.10%), American Capital Management Inc. (4.64%), Wellington Management Group LLP (4.18%) and Daruma Capital Management LLC (2.59%). Company insiders that own OraSure Technologies stock include Anthony Zezzo II, Brian Smith, Charles W Patrick, Douglas A Michels, Jack E Jerrett, Mara G Aspinall, Roberto Cuca, Ronald H Spair, Ronny B Lancaster and Stephen S Phd Tang. View Institutional Ownership Trends for OraSure Technologies.

Which institutional investors are selling OraSure Technologies stock?

OSUR stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Marshall Wace LLP, Emerald Advisers LLC, Penn Capital Management Co. Inc., Penn Capital Management Co. Inc., Los Angeles Capital Management & Equity Research Inc., Systematic Financial Management LP and Daruma Capital Management LLC. Company insiders that have sold OraSure Technologies company stock in the last year include Charles W Patrick and Stephen S Phd Tang. View Insider Buying and Selling for OraSure Technologies.

Which institutional investors are buying OraSure Technologies stock?

OSUR stock was acquired by a variety of institutional investors in the last quarter, including American Capital Management Inc., Neuberger Berman Group LLC, Wellington Management Group LLP, Dimensional Fund Advisors LP, BlackRock Inc., Renaissance Technologies LLC, Oxford Asset Management LLP and Cornercap Investment Counsel Inc.. Company insiders that have bought OraSure Technologies stock in the last two years include Jack E Jerrett, Mara G Aspinall, Roberto Cuca and Stephen S Phd Tang. View Insider Buying and Selling for OraSure Technologies.

How do I buy shares of OraSure Technologies?

Shares of OSUR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is OraSure Technologies' stock price today?

One share of OSUR stock can currently be purchased for approximately $8.21.

How big of a company is OraSure Technologies?

OraSure Technologies has a market capitalization of $509.43 million and generates $181.74 million in revenue each year. The medical instruments supplier earns $20.40 million in net income (profit) each year or $0.50 on an earnings per share basis. OraSure Technologies employs 398 workers across the globe.

What is OraSure Technologies' official website?

The official website for OraSure Technologies is http://www.orasure.com/.

How can I contact OraSure Technologies?

OraSure Technologies' mailing address is 220 EAST FIRST STREET, BETHLEHEM PA, 18015. The medical instruments supplier can be reached via phone at 610-882-1820 or via email at [email protected]


MarketBeat Community Rating for OraSure Technologies (NASDAQ OSUR)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  454 (Vote Outperform)
Underperform Votes:  321 (Vote Underperform)
Total Votes:  775
MarketBeat's community ratings are surveys of what our community members think about OraSure Technologies and other stocks. Vote "Outperform" if you believe OSUR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OSUR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 5/27/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel